Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies
Identifieur interne : 003300 ( Main/Exploration ); précédent : 003299; suivant : 003301Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies
Auteurs : Kaveh M. Koochesfahani [Canada] ; Raúl De La Fuente-Fernández [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Basal Ganglia (drug effects), Basal Ganglia (radionuclide imaging), Caudate Nucleus (drug effects), Caudate Nucleus (radionuclide imaging), Central Nervous System Stimulants (administration & dosage), Dopamine, Dopamine (metabolism), Dopamine D2 Receptor Antagonists, Dopamine Plasma Membrane Transport Proteins (antagonists & inhibitors), Emission tomography, Extracellular Fluid (drug effects), Female, Human, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Male, Methylphenidate, Methylphenidate (administration & dosage), Middle Aged, Nervous system diseases, Oral administration, Parkinson Disease (drug therapy), Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease, Positron, Positron emission tomography, Positron-Emission Tomography, Putamen (drug effects), Putamen (radionuclide imaging), Raclopride, Raclopride (diagnostic use), Raclopride (pharmacokinetics), Release, Treatment Failure, dopamine release, dopamine transporter, methylphenidate, positron emission tomography, raclopride.
- MESH :
- chemical , administration & dosage : Central Nervous System Stimulants, Methylphenidate.
- chemical , antagonists & inhibitors : Dopamine Plasma Membrane Transport Proteins.
- chemical , diagnostic use : Raclopride.
- drug effects : Basal Ganglia, Caudate Nucleus, Extracellular Fluid, Putamen.
- drug therapy : Parkinson Disease.
- chemical , metabolism : Dopamine.
- chemical , pharmacokinetics : Raclopride.
- radionuclide imaging : Basal Ganglia, Caudate Nucleus, Parkinson Disease, Putamen.
- Administration, Oral, Adult, Aged, Dopamine D2 Receptor Antagonists, Female, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Male, Middle Aged, Positron-Emission Tomography, Treatment Failure.
Abstract
In this study, we assessed the changes of endogenous dopamine (DA) levels in response to methylphenidate in 5 patients with idiopathic Parkinson's disease (PD) and 6 healthy controls. Three‐dimensional positron emission tomography was performed with the D2 receptor antagonist [11C]raclopride (RAC) at baseline and 1 hour following the administration of oral methylphenidate (0.8 mg/kg) to assess changes in dopamine levels indirectly. Oral methylphenidate produced no significant change in extracellular DA levels in the putamen, as estimated by comparing changes in RAC binding at baseline and 1 hour following its administration in PD subjects and healthy controls. However, there were small changes in RAC binding of opposite direction in caudate and ventral striatal regions compared between the two groups. Although there was no consistent improvement in motor function in the PD group, some patients did experience a subjective high in response to methylphenidate (MP). Failure of oral MP to alter extracellular DA levels in putamen could result from degeneration of presynaptic dopaminergic terminals, with consequent severe reductions in the levels of endogenous DA and dopamine transporter in PD subjects. Our data provide in vivo neurochemical support for the lack of clinical efficacy following MP in PD patients and are also in keeping with reduced DA release following amphetamine in PD subjects. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20857
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001881
- to stream Istex, to step Curation: 001881
- to stream Istex, to step Checkpoint: 001D59
- to stream PubMed, to step Corpus: 002D08
- to stream PubMed, to step Curation: 002D08
- to stream PubMed, to step Checkpoint: 002B93
- to stream Ncbi, to step Merge: 001623
- to stream Ncbi, to step Curation: 001623
- to stream Ncbi, to step Checkpoint: 001623
- to stream Main, to step Merge: 004613
- to stream PascalFrancis, to step Corpus: 001A85
- to stream PascalFrancis, to step Curation: 001236
- to stream PascalFrancis, to step Checkpoint: 001987
- to stream Main, to step Merge: 004A82
- to stream Main, to step Curation: 003300
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies</title><author><name sortKey="Koochesfahani, Kaveh M" sort="Koochesfahani, Kaveh M" uniqKey="Koochesfahani K" first="Kaveh M." last="Koochesfahani">Kaveh M. Koochesfahani</name></author><author><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name></author><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name></author><author><name sortKey="Yatham, Lakshmi N" sort="Yatham, Lakshmi N" uniqKey="Yatham L" first="Lakshmi N." last="Yatham">Lakshmi N. Yatham</name></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name></author><author><name sortKey="Blinder, Stephan" sort="Blinder, Stephan" uniqKey="Blinder S" first="Stephan" last="Blinder">Stephan Blinder</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:513EACC3010614A7098C063D1193A568A84895A7</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20857</idno><idno type="url">https://api.istex.fr/document/513EACC3010614A7098C063D1193A568A84895A7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001881</idno><idno type="wicri:Area/Istex/Curation">001881</idno><idno type="wicri:Area/Istex/Checkpoint">001D59</idno><idno type="wicri:doubleKey">0885-3185:2006:Koochesfahani K:oral:methylphenidate:fails</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16570297</idno><idno type="wicri:Area/PubMed/Corpus">002D08</idno><idno type="wicri:Area/PubMed/Curation">002D08</idno><idno type="wicri:Area/PubMed/Checkpoint">002B93</idno><idno type="wicri:Area/Ncbi/Merge">001623</idno><idno type="wicri:Area/Ncbi/Curation">001623</idno><idno type="wicri:Area/Ncbi/Checkpoint">001623</idno><idno type="wicri:doubleKey">0885-3185:2006:Koochesfahani K:oral:methylphenidate:fails</idno><idno type="wicri:Area/Main/Merge">004613</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0393859</idno><idno type="wicri:Area/PascalFrancis/Corpus">001A85</idno><idno type="wicri:Area/PascalFrancis/Curation">001236</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001987</idno><idno type="wicri:doubleKey">0885-3185:2006:Koochesfahani K:oral:methylphenidate:fails</idno><idno type="wicri:Area/Main/Merge">004A82</idno><idno type="wicri:Area/Main/Curation">003300</idno><idno type="wicri:Area/Main/Exploration">003300</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies</title><author><name sortKey="Koochesfahani, Kaveh M" sort="Koochesfahani, Kaveh M" uniqKey="Koochesfahani K" first="Kaveh M." last="Koochesfahani">Kaveh M. Koochesfahani</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Division of Neurology, Hospital Arquitecto Marcide, Ferrol</wicri:regionArea><wicri:noRegion>Ferrol</wicri:noRegion></affiliation></author><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Yatham, Lakshmi N" sort="Yatham, Lakshmi N" uniqKey="Yatham L" first="Lakshmi N." last="Yatham">Lakshmi N. Yatham</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>UBC PET/TRIUMF Group, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Blinder, Stephan" sort="Blinder, Stephan" uniqKey="Blinder S" first="Stephan" last="Blinder">Stephan Blinder</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>UBC PET/TRIUMF Group, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-07">2006-07</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="970">970</biblScope><biblScope unit="page" to="975">975</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">513EACC3010614A7098C063D1193A568A84895A7</idno><idno type="DOI">10.1002/mds.20857</idno><idno type="ArticleID">MDS20857</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (radionuclide imaging)</term><term>Caudate Nucleus (drug effects)</term><term>Caudate Nucleus (radionuclide imaging)</term><term>Central Nervous System Stimulants (administration & dosage)</term><term>Dopamine</term><term>Dopamine (metabolism)</term><term>Dopamine D2 Receptor Antagonists</term><term>Dopamine Plasma Membrane Transport Proteins (antagonists & inhibitors)</term><term>Emission tomography</term><term>Extracellular Fluid (drug effects)</term><term>Female</term><term>Human</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Imaging, Three-Dimensional</term><term>Male</term><term>Methylphenidate</term><term>Methylphenidate (administration & dosage)</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Oral administration</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Positron</term><term>Positron emission tomography</term><term>Positron-Emission Tomography</term><term>Putamen (drug effects)</term><term>Putamen (radionuclide imaging)</term><term>Raclopride</term><term>Raclopride (diagnostic use)</term><term>Raclopride (pharmacokinetics)</term><term>Release</term><term>Treatment Failure</term><term>dopamine release</term><term>dopamine transporter</term><term>methylphenidate</term><term>positron emission tomography</term><term>raclopride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Raclopride</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Caudate Nucleus</term><term>Extracellular Fluid</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Raclopride</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Basal Ganglia</term><term>Caudate Nucleus</term><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Dopamine D2 Receptor Antagonists</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Imaging, Three-Dimensional</term><term>Male</term><term>Middle Aged</term><term>Positron-Emission Tomography</term><term>Treatment Failure</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term><term>Homme</term><term>Libération</term><term>Méthylphénidate</term><term>Parkinson maladie</term><term>Positon</term><term>Raclopride</term><term>Système nerveux pathologie</term><term>Tomographie émission positon</term><term>Tomoscintigraphie</term><term>Voie orale</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this study, we assessed the changes of endogenous dopamine (DA) levels in response to methylphenidate in 5 patients with idiopathic Parkinson's disease (PD) and 6 healthy controls. Three‐dimensional positron emission tomography was performed with the D2 receptor antagonist [11C]raclopride (RAC) at baseline and 1 hour following the administration of oral methylphenidate (0.8 mg/kg) to assess changes in dopamine levels indirectly. Oral methylphenidate produced no significant change in extracellular DA levels in the putamen, as estimated by comparing changes in RAC binding at baseline and 1 hour following its administration in PD subjects and healthy controls. However, there were small changes in RAC binding of opposite direction in caudate and ventral striatal regions compared between the two groups. Although there was no consistent improvement in motor function in the PD group, some patients did experience a subjective high in response to methylphenidate (MP). Failure of oral MP to alter extracellular DA levels in putamen could result from degeneration of presynaptic dopaminergic terminals, with consequent severe reductions in the levels of endogenous DA and dopamine transporter in PD subjects. Our data provide in vivo neurochemical support for the lack of clinical efficacy following MP in PD patients and are also in keeping with reduced DA release following amphetamine in PD subjects. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>Espagne</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Koochesfahani, Kaveh M" sort="Koochesfahani, Kaveh M" uniqKey="Koochesfahani K" first="Kaveh M." last="Koochesfahani">Kaveh M. Koochesfahani</name></noRegion><name sortKey="Blinder, Stephan" sort="Blinder, Stephan" uniqKey="Blinder S" first="Stephan" last="Blinder">Stephan Blinder</name><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><name sortKey="Yatham, Lakshmi N" sort="Yatham, Lakshmi N" uniqKey="Yatham L" first="Lakshmi N." last="Yatham">Lakshmi N. Yatham</name></country><country name="Espagne"><noRegion><name sortKey="De La Fuente Ernandez, Raul" sort="De La Fuente Ernandez, Raul" uniqKey="De La Fuente Ernandez R" first="Raúl" last="De La Fuente-Fernández">Raúl De La Fuente-Fernández</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003300 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003300 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:513EACC3010614A7098C063D1193A568A84895A7
|texte= Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies
}}
| This area was generated with Dilib version V0.6.23. |  |